➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim

Last Updated: March 8, 2021

DrugPatentWatch Database Preview

PLENVU Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Plenvu, and what generic alternatives are available?

Plenvu is a drug marketed by Salix and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixteen patent family members in thirty-five countries.

The generic ingredient in PLENVU is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.

US ANDA Litigation and Generic Entry Outlook for Plenvu

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for PLENVU
Drug patent expirations by year for PLENVU
Drug Prices for PLENVU

See drug prices for PLENVU

Recent Clinical Trials for PLENVU

Identify potential brand extensions & 505(b)(2) entrants

Fundacion Clinic per a la Recerca BiomédicaPhase 4
Hospital Clinic of BarcelonaPhase 4
Casen Recordati S.L.Phase 4

See all PLENVU clinical trials

Paragraph IV (Patent) Challenges for PLENVU

US Patents and Regulatory Information for PLENVU

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.